Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 22, 2017. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a single share acquisition transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares following the exercise of options under the Company's ShareSave Plan.
- Transaction Date: May 19, 2017.
- Volume: 288 shares.
- Price: £12.47 per share.
- Location: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses the change in shareholding for a specific individual.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this filing. The document is a regulatory disclosure of a transaction by a Person Discharging Managerial Responsibilities (PDMR).
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Mr. P C Thomson, President of Global Affairs.
- Option Details: The shares were acquired by exercising options originally granted on October 30, 2013.
- Transaction Scale: The volume of 288 shares represents a negligible impact on total company equity.
- Financial Data Absence: Investors should note that this filing contains no quarterly or annual financial performance metrics.